INNOVATION ACTA S.R.L. -  

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2019
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000

Ranking timeline:

Project Participation Performance(2018-01-01 - 2024-12-31 ):

Total Project Funding:

Funding per Partner:

Projects:

Leadership:

Total number of projects: 12
As coordinator: 0
As participant: 12
Sole participant: 0
Coordinator / Participant Ratio: 0*

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2023 0 10.097.698 305.364 2
2022 0 11.635.981 833.370 3
2020 0 15.994.651 581.504 2
2019 0 22.337.396 1.313.600 3
2018 0 11.175.701 83.225 2

Networking:

Partners:

Institution:Projects [No]:
CHARITE UNIVERSITAETSMEDIZIN BERLIN5
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS3
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD3
TISSUSE3
BE THE PARTNER INC2
CELL THERAPY CATAPULT LIMITED2
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH2
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA2
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE2
INSTITUT PASTEUR2
KATHOLIEKE UNIVERSITEIT LEUVEN2
MILTENYI BIOTEC BV & CO KG2
PLURISTEM2
REGION SYDDANMARK2
UNIVERSIDADE DO MINHO2
UNIVERSITAET ZUERICH2
ACADEMIC MEDICAL CENTRE AMSTERDAM1
ACADEMISCH ZIEKENHUIS GRONINGEN1
AHEAD THERAPEUTICS SL1
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRL ALTA1
ANICELLS1
ASSOCIATION FRANCAISE GOUGEROTSJOGREN1
AZIENDA OSPEDALE UNIVERSITA PADOVA1
BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION1
BAYERISCHE JULIUS MAXIMILIANS UNIVERSITAET WUERZBURG1
BE THE PARTNER1
BIOKIT RESEARCH & DEVELOPMENT SLU1
BRISTOLMYERS SQUIBB COMPANY CORP1
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES1
CHECKIMMUNE1
CONSIGLIO NAZIONALE DELLE RICERCHE1
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER1
CONSORCIO MAR PARC DE SALUT DE BARCELONA1
DRESDEN UNIVERSITY OF TECHNOLOGY1
DUKE UNIVERSITY1
ECHOSENS1
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK1
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM1
EUROPAISCHER NIERENPATIENTENVERBAND1
EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER1
EUROPEAN HEMATOLOGY ASSOCIATION1
EUROPEAN LIVER PATIENTS ASSOCIATION1
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA1
FONDAZIONE POLIAMBULANZA1
FONDAZIONE TELETHON1
FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH1
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS1
FUNDACAO CALOUSTE GULBENKIAN1
FUNDACIO INSTITUT UNIVERSITARI PERA LA RECERCA A L'ATENCIO PRIMARIA DE SALUT JORDI GOL I GURINA1
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD1
FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III1
GENESIS BIOMED1
GENOMIC VISION1
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT1
HEIDELBERG PHARMA RESEARCH1
HELMHOLTZZENTRUM DRESDENROSSENDORF EV1
HELSE STAVANGER HF1
HOPITAUX UNIVERSITAIRES DE STRASBOURG1
HOSPITAL CLINIC DE BARCELONA1
HYCULT BIOTECHNOLOGY BV1
ICON CLINICAL RESEARCH LIMITED1
IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE1
IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION1
IMMUDEX APS1
INNOVAMOL CONSULTING1
INSTITUT CATALA DE LA SALUT1
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS1
INTERNATIONAL OSTEOPOROSIS FOUNDATION1
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT1
KAROLINSKA INSTITUTE1
KINETO TECH REHAB1
KLINICKA BOLNICA DUBRAVA ZAGREB1
LEIBNIZ INSTITUT FUR NATURSTOFF FORSCHUNG UND INFEKTIONSBIOLOGIE EV HANS KNOLL INSTITUTE1
LUMICKS BV1
MEDIZINISCHE HOCHSCHULE HANNOVER1
MILTENYI BIOTEC1
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS1
NATIONAL UNIVERSITY OF IRELAND GALWAY1
NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN1
NORDIC BIOSCIENCE1
NOVARTIS PHARMA1
NOVIMMUNE1
OSLO UNIVERSITETSSYKEHUS HF1
OULUN YLIOPISTO1
OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST1
PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG PRIVATSTIFTUNG1
PLASTICELL LIMITED1
PLURI BIOTECH1
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON1
QUEENSLAND UNIVERSITY OF TECHNOLOGY QLD QUT1
ROYAL COLLEGE OF SURGEONS IN IRELAND1
SEMMELWEIS UNIVERSITY OF MEDICINE1
SORBONNE UNIVERSITE1
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM1
STICHTING RADBOUD UNIVERSITEIT1
STICHTING REUMANEDERLAND1
STICHTING SANQUIN BLOEDVOORZIENING1
STICHTING VUMC1

Constancy:

Total number of partners: 168
Partner loyalty:
Frequent Partner: (> 2 projects): 14
Rare Partner: 154
Frequent / Rare Partner Ratio: 0.09

Project overview:

Start dateProjectacronymrolefundingpartners
2023-01-01Cohesin and its regulators: from chromosome dynamics and nuclear architecture to human diseases CohesiNetparticipant2.649.82320
2023-01-01PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIENT OUTCOMES PROTOparticipant7.447.87510
2022-10-01An integrated approach to restore tolerance in autoimmune disease TOLERATEparticipant2.109.65018
2022-09-01FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS T-FITNESSparticipant3.789.4727
2022-07-01Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology geneTIGAparticipant5.736.85911
2020-01-01Screening for liver fibrosis - population-based study across European countries LiverScreenparticipant5.996.48123
2020-01-01Host directed medicine in invasive fungal infection HDM-FUNparticipant9.998.17018
2019-03-01RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients RESTOREparticipant1.000.00011
2019-01-01Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials RESHAPEparticipant13.137.39610
2019-01-01NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients NECESSITYparticipant8.200.00025
2018-11-01Integrating chemical and biological approaches to target NAD production and signaling in cancer INTEGRATAparticipant3.738.57315
2018-01-01Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial HIPGENparticipant7.437.12812